Transgenic plant cells and plants having an increased glycolysis rate

Transgenic plant cells and plants having an increased glycolysis rate

l > An expression control sequence for general and effective expression of genes in plants (C Baszczynski et a/, US) Pioneer Hi-Bred International In...

145KB Sizes 2 Downloads 81 Views

l

> An expression control sequence for general and effective expression of genes in plants (C Baszczynski et a/, US) Pioneer Hi-Bred International Inc N” WO 97/05260, PCT. > Root cortex specific gene promoter (M Conkling et al, US) North Carolina State University and the inventors N” WO 97/05261, PCT. An isolated DNA molecule comprises a DNA promoter sequence which directs root cortex specific transcription of a dowstream heterologous DNA segment in a plant cell... Transformed plants, such as tobacco plants, comprise transformed plant cell containing a heterologous DNA construct comprising an expression cassette... > Processes for the production of amidase (Y Armitage and J Hughes, UK) Alllied Colloids Ltd and the inventors N” WO 97/06248, PCT. ... Novel enzymes have particular stability. A novel microorganism is Rhodococcus rhodochrous NCIMB 40756 and is capable of producing a particularly stable amidase... z Inducible herbicide resistance (I Jepson, UK) Zeneca Ltd and the inventor N” WO 97/06269. PCT. ... The inducible effect may be achieved by using a gene switch such as the alcA/alcR switch derived from A nidulans. The invention relates in particular to inducible resistance to the herbicide Nphosphonomethyl glycine (glyphosate) and its salts. > Regulation of plant development and physiology through plasmodesmatal macromolecular transport

les derniers brevets deposes : morceaux choisis r6aliske en collaboration avec I’lnpi

of proteins and oligonucleotides (L Wiiiiam, US) The Regents of the University of California N” WO 97/06669, PCT. Tobacco mosaic virus movement protein (TMV-MI’) in wild type and mutant forms is shown and used to affect plant size, carbon metabolism and biomass partitioning. Use of a protein to mediate its own cell-to-cell transport through plasmodesmata is illustrated with wild type and mutant forms of knotted protein from the maize homeobox gene Knotted. > Methods and materials for producing pathogenresistant plants (E Hiebert et al, US) University of Florida N” WO 97/07217, PCT. ... comprise a mutant plant virus gene which confers resistance on tobacco and tomato plants against tobacco mosaic tobamovirus and tomato mottle geminivirus infections and infection by other related geminiviruses... > Transgenic plant cells and plants having an increased glycolysis rate (R Trethewey and L Willmitz~, DE) J Riesmeier and the inventors N” WO 97/07221, PCT. ... The glycolysis rate is increased by the introduction and expression in plants cells of a DNA sequence which codes for an invertase, preferably a deregulated or unregulated invertase, and a DNA sequence which codes for a hexokinase, preferably a deregulated or unregulated hexokinase. > Production of transgenit plants comprising the winged bean lysine-rich protein (S Sun et a/, HK, US, CN) University of Hawaii N” WO 97/07665, PCT. A lysine-rich protein gene has been cloned from winged bean, Psophocarpus tetragonolobus and its DNA sequence and deduced protein sequence are disclosed. Methods for transforming plants cells are provided that mature

into plants having elevated levels of lysine in their seeds.

et p~ptid~s > Anticoagulant factor Va derivatives (J Rosing et a/, NL, AT) lmmuno AG N” 761686, EP. ... which can be used in treating patients for a hypercoagulant condition, thrombosis or thromboembolic disease. There is also disclosed a method for preparing novel anticoagulant factor Va derivatives. > Mocamagin, a cobra venom protease, and therapeutic uses thereof (M Berndt et a/, AU) The inventors N” WO 97/05244, PCT. > cDNA sequence, aminoacid sequence derived from the cDNA sequence, of the precursor protein of human GCAP-ll/uroguanyline, and amino-acid sequence of the fragment circulating in human blood (0 Hill et a/, DE) WG Forssmann and the inventors N” WO 97/06258, PCT. ...The GCAP-II circulating in human blood is identical to the synthetic GCAP-II reference substance, but not to other peptides or its fragments... A different biological activity and differences in the three-dimensional peptide structure of GCAPII compared with other GCAP-II fragments show that this GCAP-II fragment is a high-quality natural peptide... which is suitable for use in treating numerous conditions which progress hand in hand with electrolyte-transport disorders in cells as well as for use in treating, in particular, diseases of endocrine organs...

Diagnostic > Pharmaceutical compositions for competitively inhibiing the binding of a retmvirus to the IFN-receptor and means for diagnosis of

l

an HIV infection (M Dierich and Y Chen, CN, AT) Dr Rentschler Biotechnologie GmbH and the inventors N” WO 97/06818, PCT. ... relates to a combination of substances for the diagnosis of an HIV infection which is based on the detection of the interaction between HIV-gp41 and the IFN-a-&receptor. z Materials and methods for detection and treatment of insulin-dependent diabetes (N MacLaren et al, US) The Government of the United States, the Secretary Department of Health and Human Services N” WO 97/07211, PCT. z Immunotherapy medicaments containing antibodies which specifically detect the MHCII antigen of a patient to be treated (H Lindhofer and S Thierfelder, DE) GSF Forschungszentrum fur Umwelt und Gesundheit GmbH and the inventors N” WO 97/07819, PCT.

Vaccin z Mild Newcastle disease virus vaccine (C Schrier, W Akzo Nobel NV N” 760394, EP. . .. is able to induce a solid immune response in poultry without adverse vaccination reactions. r Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine (G Jackson et a/, CA) Connaught Laboratories Ltd N” 761230, EP. A component vaccine against disease caused by infection by Bordetella pertussis, characterized by... two other purified non-Bordetella antigens which are diphteria toxoid (D) and tetanus toxoid (T) and a pharmaceutically-acceptable carrier therefor. > Hybrid protein comprising T-helper cell stimulaBIOFUTUR167 l Mai 1997 45